Zobrazeno 1 - 10
of 294
pro vyhledávání: '"Ted A, Skolarus"'
Autor:
Jennifer Dunsmore, Eilidh Duncan, Sara J. MacLennan, James N'Dow, Philip Cornford, Francesco Esperto, Nicola Pavan, María J. Ribal, Monique J. Roobol, Ted A. Skolarus, Steven MacLennan
Publikováno v:
BJUI Compass, Vol 5, Iss 9, Pp 874-884 (2024)
Abstract Objectives To understand how best to further reduce the inappropriate use of pre‐surgical androgen deprivation therapy (ADT), we investigated the determinants (influences) of ADT prescribing in urologists in two European countries using an
Externí odkaz:
https://doaj.org/article/4dbf9e469100447f9a5958761c7278b7
Autor:
Ted A. Skolarus, Sarah T. Hawley, Jane Forman, Anne E. Sales, Jordan B. Sparks, Tabitha Metreger, Jennifer Burns, Megan V. Caram, Archana Radhakrishnan, Lesly A. Dossett, Danil V. Makarov, John T. Leppert, Jeremy B. Shelton, Kristian D. Stensland, Jennifer Dunsmore, Steven Maclennan, Sameer Saini, Brent K. Hollenbeck, Vahakn Shahinian, Daniela A. Wittmann, Varad Deolankar, S. Sriram
Publikováno v:
Implementation Science Communications, Vol 5, Iss 1, Pp 1-13 (2024)
Abstract Background Many men with prostate cancer will be exposed to androgen deprivation therapy (ADT). While evidence-based ADT use is common, ADT is also used in cases with no or limited evidence resulting in more harm than benefit, i.e., overuse.
Externí odkaz:
https://doaj.org/article/edf770c1937947e5bba9b2a128e51551
Autor:
Megan E. V. Caram, Kyle Kumbier, Phoebe A. Tsao, Jennifer Burns, Jordan B. Sparks, Kristian D. Stensland, Zachery R. Reichert, Joshi J. Alumkal, Brent K. Hollenbeck, Vahakn Shahinian, Alexander Tsodikov, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different
Externí odkaz:
https://doaj.org/article/e87d252553e64f07b78df5cbebfcca3e
Autor:
Phoebe A. Tsao, Jennifer Burns, Kyle Kumbier, Jordan B. Sparks, Shami Entenman, Lindsey E. Bloor, Amy S. B. Bohnert, Ted A. Skolarus, Megan E. V. Caram
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16490-16501 (2023)
Abstract Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. Methods We used national Veter
Externí odkaz:
https://doaj.org/article/d95095a5a3ee48ecb1498054bf1924b9
Autor:
Lalita Subramanian, Sarah T. Hawley, Ted A. Skolarus, Aaron Rankin, Michael D. Fetters, Karla Witzke, Jason Chen, Archana Radhakrishnan
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Prostate cancer is the most common cancer among men in the United States. Treatment guidelines recommend active surveillance for low‐risk prostate cancer, which involves monitoring for progression, to avoid or delay definitive t
Externí odkaz:
https://doaj.org/article/da6b74f05abb426eb71b3b84c4a01cf8
Autor:
Kristian D. Stensland, Anne E. Sales, Varsha K. Vedapudi, Laura J. Damschroder, Ted A. Skolarus
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-22 (2023)
Abstract Introduction Cancer clinical trials can be considered evidence-based interventions with substantial benefits, but suffer from poor implementation leading to low enrollment and frequent failure. Applying implementation science approaches such
Externí odkaz:
https://doaj.org/article/a3c0f30533de4c5e9d7118a8d9708293
Autor:
Tayana Soukup, David Winters, Kia‐Chong Chua, Philip Rowland, Jacqueline Moneke, Ted A. Skolarus, Rasiah Bharathan, Leanne Harling, Anish Bali, Viren Asher, Tasha Gandamihardja, Nick Sevdalis, James S. A. Green, Benjamin W. Lamb
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8729-8741 (2023)
Abstract Background It is not well understood the overall changes that multidisciplinary teams (MDTs) have had to make in response to the COVID‐19 pandemic, nor the impact that such changes, in addition to the other challenges faced by MDTs, have h
Externí odkaz:
https://doaj.org/article/549ceee744b34b458984e367cdd0b91c
Autor:
Megan E. V. Caram, Kyle Kumbier, Jennifer Burns, Jordan B. Sparks, Phoebe A. Tsao, Kristian D. Stensland, Samuel L. Washington III, Brent K. Hollenbeck, Vahakn Shahinian, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6945-6955 (2023)
Abstract Background Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide
Externí odkaz:
https://doaj.org/article/8e7c0dabb2ab4edb91d46c692eb5454b
Publikováno v:
Implementation Science Communications, Vol 3, Iss 1, Pp 1-13 (2022)
Abstract Background Clinical trials advance science, benefit society, and provide optimal care to individuals with some conditions, such as cancer. However, clinical trials often fail to reach their endpoints, and low participant enrollment remains a
Externí odkaz:
https://doaj.org/article/cb565679c8284c1da53d60ae53252749
Publikováno v:
Learning Health Systems, Vol 7, Iss 2, Pp n/a-n/a (2023)
Abstract Clinical trials generate key evidence to inform decision making, and also benefit participants directly. However, clinical trials frequently fail, often struggle to enroll participants, and are expensive. Part of the problem with trial condu
Externí odkaz:
https://doaj.org/article/ae8396252b7a46018867bdbb40232576